Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL)

At present, the use of the common chemotherapy regimen CHOP/R-CHOP for diffuse large B-cell lymphoma (DLBCL) has some shortcomings, especially for relapsed and refractory DLBCL. CD47 is now considered as a prominent target in cancer therapies, and CD47 blockade mainly inhibits the CD47-SIRPα axis to...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wenqi, Fan, Yanfeng, Li, Meng, Yang, Linqi, Zhang, Zhenya, Liu, Lihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463246/
https://www.ncbi.nlm.nih.gov/pubmed/34567285
http://dx.doi.org/10.1155/2021/4894022
_version_ 1784572360834154496
author Zhang, Wenqi
Fan, Yanfeng
Li, Meng
Yang, Linqi
Zhang, Zhenya
Liu, Lihong
author_facet Zhang, Wenqi
Fan, Yanfeng
Li, Meng
Yang, Linqi
Zhang, Zhenya
Liu, Lihong
author_sort Zhang, Wenqi
collection PubMed
description At present, the use of the common chemotherapy regimen CHOP/R-CHOP for diffuse large B-cell lymphoma (DLBCL) has some shortcomings, especially for relapsed and refractory DLBCL. CD47 is now considered as a prominent target in cancer therapies, and CD47 blockade mainly inhibits the CD47-SIRPα axis to prevent tumor immune escape. Here, we evaluated the effects of the latest CD47 antibodies reported and the correlations of closely related genes with CD47 in this disease. In the future, therapeutic strategies for DLBCL will focus on multitarget antibody combined treatment and multigene joint attacks.
format Online
Article
Text
id pubmed-8463246
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-84632462021-09-25 Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL) Zhang, Wenqi Fan, Yanfeng Li, Meng Yang, Linqi Zhang, Zhenya Liu, Lihong Dis Markers Review Article At present, the use of the common chemotherapy regimen CHOP/R-CHOP for diffuse large B-cell lymphoma (DLBCL) has some shortcomings, especially for relapsed and refractory DLBCL. CD47 is now considered as a prominent target in cancer therapies, and CD47 blockade mainly inhibits the CD47-SIRPα axis to prevent tumor immune escape. Here, we evaluated the effects of the latest CD47 antibodies reported and the correlations of closely related genes with CD47 in this disease. In the future, therapeutic strategies for DLBCL will focus on multitarget antibody combined treatment and multigene joint attacks. Hindawi 2021-09-16 /pmc/articles/PMC8463246/ /pubmed/34567285 http://dx.doi.org/10.1155/2021/4894022 Text en Copyright © 2021 Wenqi Zhang et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Zhang, Wenqi
Fan, Yanfeng
Li, Meng
Yang, Linqi
Zhang, Zhenya
Liu, Lihong
Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL)
title Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL)
title_full Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL)
title_fullStr Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL)
title_full_unstemmed Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL)
title_short Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL)
title_sort therapy strategy of cd47 in diffuse large b-cell lymphoma (dlbcl)
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463246/
https://www.ncbi.nlm.nih.gov/pubmed/34567285
http://dx.doi.org/10.1155/2021/4894022
work_keys_str_mv AT zhangwenqi therapystrategyofcd47indiffuselargebcelllymphomadlbcl
AT fanyanfeng therapystrategyofcd47indiffuselargebcelllymphomadlbcl
AT limeng therapystrategyofcd47indiffuselargebcelllymphomadlbcl
AT yanglinqi therapystrategyofcd47indiffuselargebcelllymphomadlbcl
AT zhangzhenya therapystrategyofcd47indiffuselargebcelllymphomadlbcl
AT liulihong therapystrategyofcd47indiffuselargebcelllymphomadlbcl

Ejemplares similares